Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.19% on an annualized basis producing an average annual return of 21.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.05 billion.

Benzinga

Trading Volume Is Falling — And These Exchange Stocks Are Getting Hit

As financial markets have weakened in 2022, trading volumes have fallen across all asset classes, according to a new report by Bank of America analyst Craig Siegenthaler.

Benzinga

Double Digits: General Motors Is Making Only This Many Hummer EVs Per Day

One of the largest traditional automotive companies has put forth a plan to increase its position in the electric vehicle industry, something that has drawn praise from President Joe Biden.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Microsoft Azure Data Centers are Operating With Limited Server Capacity: Report

Global Microsoft Corp (NASDAQ: MSFT) Azure data centers are operating with limited server capacity amid a global supply shortage,

Benzinga

Expert Ratings for Viasat

Analysts have provided the following ratings for Viasat (NASDAQ:VSAT) within the last quarter:

Benzinga

AMC Shares Pop As The Minions Return To Work

As the new installment of the Minions franchise opened Friday, AMC Entertainment Holdings, Inc. (NYSE: AMC) stock rose to $14.31 as it neared a 6% jump in value earlier in the session. AMC shares were trading negative as Friday's trading session drew to a close.

Benzinga

Stocks That Hit 52-Week Lows On Friday

On Friday, 319 stocks hit new 52-week lows.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Dow Surges 200 Points; Agile Therapeutics Shares Slide

U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining around 200 points on Friday.

Benzinga

Volcon Opens Pre-Orders For Fully Electric UTV 'Stag'

Volcon Inc (NASDAQ:VLCN) has launched an all-electric Volcon Stag utility vehicle. The company has opened pre-orders for the vehicle. The Stag has 1,550 lbs of payload and 2,000 lbs of max towing capacity (with towing mode selected). Stag's peak power is measured at 125 hp with a torque of 265 lb-ft. Including…

Benzinga

Citi Remains Unfazed By Enron Collapse Predictor's Bearishness On These Data Center Stocks

Citi analyst Michael Rollins noted data center stocks Equinix, Inc (NASDAQ:EQIX), Digital Realty Trust, Inc (NYSE:DLR), Cyxtera Technologies, Inc (NASDAQ:CYXT) were down an average of >5% on July 1 on reports (including Financial Times) that an investor is "betting against 'legacy' data centers that now face growing competition from the trio of tech giants that have been…

Benzinga

SG Blocks Inks Contract With Container Park Developer In Florida

SG Blocks Inc (NASDAQ:SGBX) has sold three 40’ containers to a private developer seeking to build a container park in Lake City, Florida. The square footage of the sale in its entirety is roughly 960 square feet. The container park plans to feature entertainment and an assortment of food trucks and alcohol vendors.…

Benzinga

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for FY23 revenue and adjusted EBITDA. While early in the selling season, ACCD won more new business in 1QF23 than…

Benzinga

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see gastrointestinal stromal tumors (GISTs) treatment space reigniting with the entrance of a Theseus' pan-KIT inhibitor THE-630, with a high likelihood of 5L approval with earlier line potential. The analysts believe THE-630 can…

Benzinga

Supreme Court Ruling Dials Back EPA Powers: What It Means For Energy Stocks

The U.S. Supreme Court continued its busy summer this week, issuing a landmark ruling limiting the mpower of the Environmental Protection Agency. The ruling could have significant financial implications for a number of energy sector stocks.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Nvidia Stock Falls In Sympathy With Micron As Economic Woes Hamper Chip Demand: What's Next?

Nvidia Corporation (NASDAQ: NVDA) reached a new 52-week low on Friday, despite the S&P 500 trading slightly higher.

Benzinga

U.S. Stocks Turn Lower; Dow Tumbles Over 100 Points

U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday.

Benzinga

Piper Sandler Maintains Neutral Rating for MarketAxess Holdings: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of MarketAxess Holdings (NASDAQ:MKTX) and lower its price target from $300.00 to $285.00. Shares of MarketAxess Holdings are trading down 0.69% over the last 24 hours, at $254.25 per share.

Benzinga

Looking At ASML Holding's Recent Whale Trades

Someone with a lot of money to spend has taken a bullish stance on ASML Holding (NASDAQ:ASML). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

JP Morgan Maintains Overweight Rating for Pinnacle Finl Partners: Here's What You Need To Know

JP Morgan has decided to maintain its Overweight rating of Pinnacle Finl Partners (NASDAQ:PNFP) and lower its price target from $123.00 to $95.00. Shares of Pinnacle Finl Partners are trading up 0.25% over the last 24 hours, at $72.49 per share.

Benzinga

Expert Ratings for Zions Bancorp

Analysts have provided the following ratings for Zions Bancorp (NASDAQ:ZION) within the last quarter:

Benzinga

HC Wainwright & Co. Maintains Buy Rating for Celldex Therapeutics: Here's What You Need To Know

HC Wainwright & Co. has decided to maintain its Buy rating of Celldex Therapeutics (NASDAQ:CLDX) and raise its price target from $60.00 to $73.00. Shares of Celldex Therapeutics are trading down 14.91% over the last 24 hours, at $22.94 per share.

Benzinga

Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) rose 56.1% to $ 0.7029 after dropping 10% on Thursday.

Benzinga

Why Borqs Technologies Shares Are Gaining Today

Borqs Technologies, Inc's (NASDAQ:BRQS) solar energy storage systems subsidiary, Holu Hou Energy LLC (HHE), collaborated with developers and property owners for nine solar plus energy storage projects in the State of Hawaii totaling $49.8 million, as of the last day of Q2, 2022. Eight of the nine projects were on the island of…

Benzinga

Apple, Microsoft, Disney And American Express Continue To Plummet: Dow Jones Index Has Worst First Half In Decades

The U.S. Stock Market has had a rough 2022 so far and the SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA: DIA) has been no exception to that. Since the start of the calendar year, the index has lost close to 6,000 points as inflation continues to rise and consumer spending falls.

Benzinga

Analyst Ratings for Enanta Pharmaceuticals

Within the last quarter, Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings:

1 … 378 379 380 381

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.